Edition:
United States

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

4.13USD
10:59am EST
Change (% chg)

$-0.28 (-6.35%)
Prev Close
$4.41
Open
$4.31
Day's High
$4.31
Day's Low
$4.10
Volume
6,360
Avg. Vol
28,095
52-wk High
$9.29
52-wk Low
$3.03

Latest Key Developments (Source: Significant Developments)

Therapix Biosciences Q2 Loss Per Share Of $0.01
Monday, 20 Aug 2018 08:30am EDT 

Aug 20 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.THERAPIX BIOSCIENCES LTD Q2 LOSS PER SHARE $0.01 .THERAPIX BIOSCIENCES LTD - CASH TOTALED $5.1 MILLION AS OF JUNE 30, 2018, COMPARED TO $9.2 MILLION AS OF DECEMBER 31, 2017.  Full Article

Dual-Listed Therapix To Voluntarily Delist From Tel Aviv Stock Exchange
Wednesday, 9 May 2018 08:35am EDT 

May 9 (Reuters) - Therapix Biosciences Ltd ::DUAL-LISTED THERAPIX TO VOLUNTARILY DELIST FROM TEL AVIV STOCK EXCHANGE.THERAPIX BIOSCIENCES LTD - DELISTING OF THERAPIX'S ORDINARY SHARES FROM TRADING ON TASE EXPECTED TO BECOME EFFECTIVE THREE MONTHS FROM DATE OF REQUEST.  Full Article

Therapix Biosciences Expects To Test THX-110 In Early Study In Q2
Wednesday, 7 Feb 2018 08:30am EST 

Feb 7 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES LTD - EXPECT TO EVALUATE THX-110 IN A PHASE IIB CLINICAL STUDY IN Q2 OF 2018.THERAPIX BIOSCIENCES - COMPLETES PRE-IND COMMUNICATION WITH FDA ON THX-110 FOR TOURETTE SYNDROME: CLINICAL DEVELOPMENT TO PROCEED AS PROJECTED.  Full Article

Therapix Biosciences Announces Expansion Into Precision Medicine Through New Fully-Owned Subsidiary
Tuesday, 9 Jan 2018 08:37am EST 

Jan 9 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES ANNOUNCES EXPANSION INTO PRECISION MEDICINE THROUGH NEW FULLY-OWNED SUBSIDIARY AND PROVIDES CORPORATE UPDATE TODAY AT THE BIOTECH SHOWCASE™ 2018.THERAPIX BIOSCIENCES LTD - ‍EXPANDING INTO PRECISION MEDICINE THROUGH A NEW FULLY-OWNED SUBSIDIARY IN ORDER TO DEVELOP "NOVEL SOLUTIONS FOR PAIN"​.  Full Article

Therapix Biosciences and Co's CFO Entered Into A "Mutually-Amicable" Separation Agreement
Tuesday, 26 Dec 2017 04:10pm EST 

Dec 26 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES SAYS CO AND CFO JOSH BLACHER ENTERED INTO A "MUTUALLY-AMICABLE" SEPARATION AGREEMENT ON DECEMBER 19 - SEC FILING.THERAPIX BIOSCIENCES SAYS IS IN THE PROCESS OF SEARCHING FOR A NEW CHIEF FINANCIAL OFFICER.  Full Article

Therapix Biosciences Q3 loss per share $0.30
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Therapix Biosciences Ltd : :Therapix Biosciences reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.30.Therapix Biosciences Ltd - ‍cash totaled $10.7 Million as of September 30, 2017, compared to $11.8 million as of June 30, 2017​.  Full Article

Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea
Wednesday, 18 Oct 2017 08:30am EDT 

Oct 18 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea.  Full Article

THERAPIX SIGNS FORMULATION DEVELOPMENT, CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01
Friday, 6 Oct 2017 08:30am EDT 

Oct 6 (Reuters) - Therapix Biosciences Ltd :THERAPIX SIGNS FORMULATION DEVELOPMENT AND CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01.THERAPIX BIOSCIENCES - ‍ENTERED EXCLUSIVE AGREEMENT WITH CATALENT PHARMA SOLUTIONS FOR FORMULATION, DEVELOPMENT AND CLINICAL MANUFACTURING OF THX-TS01​.THERAPIX BIOSCIENCES - ‍CATALENT TO DEVELOP THX-TS01 IN SOFTGEL FORM IN SUPPORT OF CO'S CLINICAL DEVELOPMENT PROGRAM.  Full Article

Therapix Biosciences posts Q2 loss per share $0.54
Thursday, 10 Aug 2017 08:00am EDT 

Aug 10 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.54.  Full Article

Therapix Biosciences and Hannover Medical School enter into clinical trial agreement
Monday, 8 May 2017 08:30am EDT 

May 8 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences and the Hannover Medical School enter into an investigator-initiated clinical trial agreement to assess the effect of txh-ts01 in patients with tourette syndrome.Therapix Biosciences - entered into trial agreement with hannover medical school to conduct proof-of-concept phase ii clinical study with lead compound, thx-ts01.Therapix Biosciences - trial agreement to conduct proof-of-concept phase ii clinical study with thx-ts01, for patients suffering from tourette syndrome.  Full Article

No consensus analysis data available.